RT Journal Article
T1 Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
A1 Bazarbachi, Ali
A1 Labopin, Myriam
A1 Angelucci, Emanuele
A1 Gülbas, Zafer
A1 Ozdogu, Hakan
A1 Arat, Mutlu
A1 de Rosa, Luca
A1 Pastano, Rocco
A1 Pioltelli, Pietro
A1 Montserrat, Rovira
A1 Martino, Massimo
A1 Ciceri, Fabio
A1 Koç, Yener
A1 Socié, Gerard
A1 Blaise, Didier
A1 Herrera, Concepcion
A1 Chalandon, Yves
A1 Bernasconi, Paolo
A1 Marotta, Giuseppe
A1 Castagna, Luca
A1 McDonald, Andrew
A1 Visani, Guiseppe
A1 Carluccio, Paola
A1 Vitek, Antonin
A1 Simand, Célestine
A1 Afanasyev, Boris
A1 Rösler, Wolf
A1 Diez-Martin, J L
A1 Nagler, Arnon
A1 Brissot, Eolia
A1 Giebel, Sebastian
A1 Mohty, Mohamad
K1 Conditioning
K1 Haploidentical stem cell transplantation
K1 T-ALL
K1 Thiotepa
K1 Total body irradiation
AB Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem cell donation. However, data are scarce on predictive factors for outcome in that setting. We identified 122 adults (20% female; median age, 31 years; range, 18 to 68 years) with T-ALL who underwent haplo-HCT with post-transplantation cyclophosphamide (ptCy) between 2010 and 2017. The median duration of follow-up of living patients was 23 months. The 2-year incidences of relapse and nonrelapse mortality were 45% and 21%, respectively. The 2-year leukemia-free survival (LFS), overall survival (OS), and graft-versus-host disease, relapse-free survival (GRFS) were 34%, 42%, and 27%, respectively. The 2-year LFS and OS were highly influenced by disease status at transplantation, being 49% and 55%, respectively, for patients in first complete remission (CR1); 34% and 50%, respectively, for those in second CR (CR2); and 8% and 12%, respectively, for patients with active disease. On multivariate analysis, only disease status was found to affect LFS and OS. Transplantation in CR2 negatively affected LFS, whereas active disease at the time of haplo-HCT negatively affected LFS and OS. In conclusion, haplo-HCT with ptCy produced encouraging results in this challenging disease, particularly when performed in patients in CR. Despite the limitation of the small sample size, our results were not affected by the type of conditioning, calling into question the need for total body irradiation-based myeloablative conditioning in that setting.
YR 2020
FD 2020-01-09
LK http://hdl.handle.net/10668/14942
UL http://hdl.handle.net/10668/14942
LA en
DS RISalud
RD Apr 6, 2025